Skip to main content
. 2017 Aug 7;5(3):58. doi: 10.3390/sports5030058

Figure 1.

Figure 1

Treatment intensification during course of disease for patients with type 2 DM (n = 126); error bars represent 95% confidence interval. SU, sulphonylurea; DPP-4i, dipeptidyl peptidase-4 inhibitors; GLP-1 RA, glucagon-like peptide receptor agonist.